-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Hkg0ANgJfLIyACyVnSbcpKrGrPQcaJUAkKdpqyd1YJS3d6f46JROdNTbKwXjmvsR szHQJNb5VSTGv4iom4Y1Vw== 0001104659-08-040169.txt : 20080616 0001104659-08-040169.hdr.sgml : 20080616 20080616164533 ACCESSION NUMBER: 0001104659-08-040169 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080611 ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20080616 DATE AS OF CHANGE: 20080616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32715 FILM NUMBER: 08901006 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 8-K 1 a08-16763_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported) June 11, 2008

 

Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

 

 

001-32715

 

94-3123681

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

135 Beaver Street Waltham, MA

 

02452

(Address of Principal Executive Offices)

 

(Zip Code)

 

(781) 398-0700

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

        o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

        o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

        o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

        o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

 

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

 

On October 23, 2002, Interleukin Genetics, Inc. (the “Company”) entered into a note purchase agreement with Pyxis Innovations Inc. (“Pyxis”), which was subsequently amended on November 13, 2002, January 28, 2003, March 5, 2003, February 23, 2006 and August 17, 2006.  Pursuant to the note purchase agreement, as amended, the Company issued and sold promissory notes in an aggregate principal amount of $2,595,336 to Pyxis.  On December 17, 2007, Pyxis converted $2,000,000 in principal and $39,679.43 in accrued interest into 3,190,987 shares of the Company’s common stock.

 

The remaining note was convertible into the Company’s common stock at a conversion price of $0.6392 per share and was due and payable on June 30, 2008.  On June 11, 2008, pursuant to the terms of the remaining note, Pyxis converted the debt, representing an aggregate principal amount of $595,336 and accrued interest of $7,450.16, into 943,032 shares of the Company’s common stock.  These shares are subject to the registration rights agreement, dated March 5, 2003, between the Company and Pyxis.

 

The offering of the note, including the shares of common stock issuable upon conversion thereof, was conducted as a private placement pursuant to the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder.

 

 

 

 

 

 

 

 

 

2


 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Interleukin Genetics, Inc.

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

 

 

Date: June 16, 2008

 

/s/ ELIOT M. LURIER

 

 

Eliot M. Lurier

 

 

Chief Financial Officer

 

 

(Signature)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----